Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=91d9c146-9346-4102-90ce-80fdb3c8e123
Date 6/12/2014
Company Name RuiYi
Mailing Address 505 Coast Blvd S. La Jolla, CA 92037 USA
Company Description RuiYi is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally.
Proceeds Purposes RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company’s lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer. RuiYi will also be advancing RYI-018 into preclinical studies. Identified via RuiYi’s iCAPS(TM) platform, RYI-018 is a first-in-class monoclonal antibody to cannabinoid receptor 1 (CB-1), a commercially validated but previously intractable drug target.